UIC-2016-058 – Breast Cancer Cell Model for PKC alpha over-expression and Tamoxifen resistance

UIC researchers have developed several clinically relevant breast cancer cell lines in order to investigate the efficacy of novel anti-tumor drugs. The T47D:A18/PKCa cell line was engineered to exogenously overexpress Protein Kinase C alpha (PKCα) which rendered it resistant to tamoxifen. A control cell line has also been generated for the PKCα expression. The cell lines have been used in in-vitro studies as well as to generate in-vivo mouse xenograft tumor models. The culture conditions, morphology and growth behavior of the cell lines are well characterized and they have been authenticated using short tandem repeat (STR) and ATCC analysis. These cell lines have been designed to test and validate novel therapeutics for tamoxifen resistant breast cancer. They are co-owned by UIC and Northwestern University. Nelson Grihalde grihalde@otm.uic.edu 312-996-4129

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More